Show simple item record

dc.contributor.authorPrevet, H
dc.contributor.authorCollins, I
dc.date.accessioned2019-03-18T11:15:51Z
dc.date.issued2019-05-24
dc.identifier.citationFuture medicinal chemistry, 2019, 11 (10), pp. 1195 - 1224
dc.identifier.issn1756-8919
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3158
dc.identifier.eissn1756-8927
dc.identifier.doi10.4155/fmc-2018-0370
dc.description.abstractDemonstrating target engagement in living systems can help drive successful drug discovery. Target engagement and occupancy studies in cells confirm direct binding of a ligand to its intended target protein and provide the binding affinity. Combined with biomarkers to measure the functional consequences of target engagement, these experiments can increase confidence in the relationship between in vitro pharmacology and observed biological effects. In this review, we focus on chemically and radioactively labelled probes as key reagents for performing such experiments. Using recent examples, we examine how the labelled probes have been employed in combination with unlabelled ligands to quantify target engagement in cells and in animals. Finally, we consider future developments of this emerging methodology.
dc.formatPrint
dc.format.extent1195 - 1224
dc.languageeng
dc.language.isoeng
dc.publisherFUTURE SCI LTD
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0
dc.subjectAnimals
dc.subjectHumans
dc.subjectFluorescent Dyes
dc.subjectDrug Evaluation, Preclinical
dc.subjectDrug Discovery
dc.subjectMolecular Targeted Therapy
dc.subjectOptical Imaging
dc.titleLabelled chemical probes for demonstrating direct target engagement in living systems.
dc.typeJournal Article
dcterms.dateAccepted2019-01-29
rioxxterms.versionofrecord10.4155/fmc-2018-0370
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-nd/4.0
rioxxterms.licenseref.startdate2019-05
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfFuture medicinal chemistry
pubs.issue10
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 2
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 2
pubs.publication-statusPublished
pubs.volume11
pubs.embargo.termsNot known
icr.researchteamMedicinal Chemistry 2
dc.contributor.icrauthorPrevet, Hugues
dc.contributor.icrauthorCollins, Ian


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0